Trial reportMedicina oral, patologia oral y cirugia bucal2015
Alpha lipoic acid efficacy in burning mouth syndrome. A controlled clinical trial.
Trial report in Medicina oral, patologia oral y cirugia bucal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- A systematic review of treatment for patients with burning mouth syndrome.Cephalalgia : an international journal of headache · 2022Pooled it
- Treatment modalities for burning mouth syndrome: a systematic review.Clinical oral investigations · 2018Pooled it
- Interventions for treating burning mouth syndrome.The Cochrane database of systematic reviews · 2016Pooled it
- Efficacy of magnesium-calcium ionic oral rinse for primary burning mouth syndrome: a randomized, double-blind, placebo-controlled trial.BMC oral health · 2026Trial
- Psychological Subtypes and Intervention Strategies in Burning Mouth Syndrome: A Narrative Review.Journal of pain research · 2026Review
- Management strategies for burning mouth syndrome: a comprehensive review.Journal of oral & facial pain and headache · 2026Review
- Efficacy of N-Acetyl Cysteine in the Treatment of Burning Mouth Syndrome-A Randomized Controlled Trial.Dentistry journal · 2025Article
- Analysis of pain prognosis, medication efficacy, treatment willingness and influencing factors in patients with burning mouth syndrome: a cross-sectional survey.BMC oral health · 2025Article
- Challenges of Diagnosis and Management of Burning Mouth Syndrome: A Literature Review.Current aging science · 2025Review
- Micronutrients status as a contributing factor in secondary burning mouth syndrome: A review of the literature.Health science reports · 2024Article
- The efficacy of alpha-lipoic acid in the management of burning mouth syndrome: An updated systematic review of randomized controlled clinical trials.Health science reports · 2023Article
- Efficacy of alpha-lipoic acid in patients with burning mouth syndrome compared to that of placebo or other interventions: a systematic review with meta-analyses.Journal of dental anesthesia and pain medicine · 2022Review
- Clinical presentation of burning mouth syndrome in patients with oral lichenoid disease.Medicina oral, patologia oral y cirugia bucal · 2020Article
- Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies.Antioxidants (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA double-blind placebo-controlled trial was conducted in order to evaluate the efficacy of alpha lipoic acid (ALA) and determine the statistical significance of the outcome variables. Burning mouth syndrome (BMS) is defined as an oral burning sensation in the absence of clinical signs which could justify the syndrome. Recent studies suggest the existence of neurological factors as a possible cause of the disease. MATERIAL AND
methods60 patients with BMS, in two groups: case group with 600 mg/day and placebo as control group; with follow up of 2 months.
results64% of ALA patients reported some level of improvement, with a level of maintenance of 68.75% one month after treatment. 27.6% of the placebo group also demonstrated some reduction in BMS symptoms.
conclusionsLong-term evolution and the intensity of symptoms are variables that reduce the probability of improvement with ALA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.